1310374-16-3

Upstream product

• 1075230-62-4 (R)-2-methylpropane-2-sulfinic acid [1-(2-fluoro-5-nitrophenyl)-(E)-ethylidene]amide 
• 1213413-42-3 (S)-3-amino-3-(2-fluoro-5-nitro-phenyl)-butyric acid methyl ester 
• 1254199-42-2 methyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-5-nitrophenyl)butanoate 
• 1075230-65-7 (S)-3-amino-3-(2-fluoro-5-nitrophenyl)butan-1-ol 
• 79110-05-7 1-(2-fluoro-5-nitrophenyl)ethanone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1301740-77-1 (S)-4-(2-fluoro-5-nitrophenyl)-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine 

Downstream Products

• 1310373-42-2 (S)-N-(3-(2-amino-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-3,5-dichloropicolinamide 
• 1310374-19-6 [(S)-4-(5-amino-2-fluoro-phenyl)-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-yl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

AMINO OXAZINE DERIVATIVES

This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula wherein R1 to R5 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.

AMINO OXAZINE DERIVATIVES

This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula (I) wherein R1 to R5 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.